Further studies which define CD180 signaling behaviour at a greater resolution will aid in developing CD180 as a prognostic biomarker and may help to highlight potential therapeutic avenues, particularly in CLL, SLE and cardiovascular pathologies. The gene discussed is CD180; the disease is B-cell chronic lymphocytic leukemia.